ASCO 2024 Abstract for Trial #23-08

Safety and activity of Diakine DK210 (EGFR), a next generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial.

Wednesday, June 19, 2024

Dr. Douglas Orr

Read the Story Here

Click the above link to view the abstract.

ASCO 2024 Poster for Trial 23-08

ASCO 2024 Poster for Trial 23-08

Click here to view the ASCO 2024 Poster for Trial 23-08 in Full-size.

Related Abstracts

Discover more abstracts for our trials.

First-in-human Phase 1/2a Trial of a Macrocyclic ATR inhibitor (ATRN-119) in Patients with Advanced Solid Tumors.

Oct 2, 2024

Dr. Reva Schneider

Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

Sep 24, 2024

Dr. Reva Schneider

First-in-human results of STX-478, a mutant-selective PI3Kα inhibitor, in advanced solid tumor patients

Sep 24, 2024

Dr. Douglas Orr
See All Posts